This ASX 200 healthcare share is up 100% in 12 months. Should you buy?

Shares in S&P/ASX 200 healthcare group Polynovo Ltd (ASX: PNV) are up 100% in the last year, but is now the time to buy on the cheap?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the S&P/ASX 200 Index (ASX: XJO) plummeting lower in 2020, shares in ASX 200 healthcare group Polynovo Ltd (ASX: PNV) are still up 102% in the last 12 months. That's good news for existing shareholders, but is there still time to buy in?

Why Polynovo shares are up 100% in the last year

I'll start by saying that Polynovo has not been immune to the recent market correction. The Polynovo share price is down 32.75% since the start of March in the current bear market. If anything, that correction makes its share price growth even more impressive.

Polynovo hit a new record high of $3.28 per share in February – 446% higher than where it started the 2019 calendar year. These are impressive numbers that put it up there with the ASX tech shares like Afterpay Ltd (ASX: APT).

The ASX 200 healthcare group specialises in burns treatment and skin cell recovery. Its NovoSorb BTM product is a dermal scaffold that helps skin regeneration when lost through surgery or burns. There's no doubt that Polynovo is making waves around the world right now. Several high-profile sales and ringing endorsements from medical experts have also pushed the share price higher.

Is it too late to buy Polynovo shares?

Polynovo CEO Paul Brennan told the Australian Financial Review on 26 February that there was "no logical basis" for the share price plummeting lower. The group does have "lumpy" revenue and is currently loss-making. In Polynovo's half-year results, the ASX 200 healthcare group recorded a 79.9% increase in half-year revenue to $10.2 million and a net loss after tax down 25.0% to $2.4 million.

I think Polynovo is definitely worth keeping an eye on right now. Since the share price started falling in late February, there have been 9 director share purchase ASX announcements. That means company insiders are seeing this as an opportunity to snap up a bargain.

If Polynovo can deliver strong revenue in August, the current $1.54 valuation could turn out to be an absolute steal.

Motley Fool contributor Ken Hall owns shares of AFTERPAY T FPO. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »